Emerald Advisers LLC Purchases 192,091 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Emerald Advisers LLC lifted its position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 29.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 835,988 shares of the specialty pharmaceutical company's stock after acquiring an additional 192,091 shares during the quarter. Emerald Advisers LLC owned approximately 1.98% of KalVista Pharmaceuticals worth $9,681,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of KALV. nVerses Capital LLC acquired a new position in KalVista Pharmaceuticals in the 2nd quarter valued at approximately $25,000. EntryPoint Capital LLC acquired a new stake in KalVista Pharmaceuticals in the first quarter valued at $92,000. China Universal Asset Management Co. Ltd. raised its position in KalVista Pharmaceuticals by 67.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company's stock worth $96,000 after purchasing an additional 3,328 shares during the last quarter. Entropy Technologies LP acquired a new position in KalVista Pharmaceuticals during the 1st quarter worth about $121,000. Finally, SG Americas Securities LLC bought a new stake in shares of KalVista Pharmaceuticals in the 3rd quarter valued at about $153,000.

Insider Buying and Selling

In other news, insider Christopher Yea sold 7,102 shares of the firm's stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $12.01, for a total value of $85,295.02. Following the completion of the sale, the insider now directly owns 84,467 shares in the company, valued at $1,014,448.67. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 14,215 shares of the company's stock in a transaction on Monday, August 19th. The shares were sold at an average price of $12.01, for a total transaction of $170,722.15. Following the transaction, the chief executive officer now owns 242,527 shares in the company, valued at approximately $2,912,749.27. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Christopher Yea sold 7,102 shares of the firm's stock in a transaction on Monday, August 19th. The shares were sold at an average price of $12.01, for a total transaction of $85,295.02. Following the completion of the transaction, the insider now directly owns 84,467 shares in the company, valued at $1,014,448.67. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,804 shares of company stock valued at $372,112 over the last ninety days. 10.50% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on KALV. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of KalVista Pharmaceuticals in a research note on Monday, September 9th. Needham & Company LLC restated a "buy" rating and set a $32.00 price target on shares of KalVista Pharmaceuticals in a report on Friday, September 6th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $20.00 price objective on shares of KalVista Pharmaceuticals in a research note on Monday, October 7th.

KalVista Pharmaceuticals Stock Performance

Shares of NASDAQ:KALV traded up $0.34 during midday trading on Friday, reaching $10.61. The company's stock had a trading volume of 281,259 shares, compared to its average volume of 204,971. KalVista Pharmaceuticals, Inc. has a fifty-two week low of $7.21 and a fifty-two week high of $16.88. The firm has a 50 day moving average price of $11.60 and a two-hundred day moving average price of $12.09. The firm has a market capitalization of $458.56 million, a price-to-earnings ratio of -3.01 and a beta of 0.92.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last issued its quarterly earnings results on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.91) by $0.04. As a group, research analysts anticipate that KalVista Pharmaceuticals, Inc. will post -3.19 earnings per share for the current year.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).